Evolent Health Announces Changes to Board of Directors
Evolent Health (NYSE: EVH) announced significant changes to its Board of Directors. Rick Jelinek, who joined as an independent director in 2023, will become Board Chair at the 2025 Annual Meeting, succeeding Cheryl Scott. Additionally, Brendan Springstubb has been appointed as a new independent director, bringing over 20 years of healthcare investment experience.
The company plans to refresh another independent director seat before the 2025 Annual Meeting through a search process led by the Board's Nominating and Governance Committee. These changes are part of Evolent's ongoing board refreshment efforts, with five new independent directors added in the past three years.
The appointments align with Evolent's commitment to strong corporate governance and shareholder collaboration. Springstubb's addition strengthens the board's capital markets and finance expertise, while Jelinek brings experience as Managing Partner of Czech One Capital Partners and former Executive VP of CVS Health.
Evolent Health (NYSE: EVH) ha annunciato cambiamenti significativi nel suo Consiglio di Amministrazione. Rick Jelinek, che è entrato come direttore indipendente nel 2023, diventerà il Presidente del Consiglio durante l'Assemblea Annuale del 2025, succedendo a Cheryl Scott. Inoltre, Brendan Springstubb è stato nominato nuovo direttore indipendente, portando con sé oltre 20 anni di esperienza negli investimenti nel settore sanitario.
L'azienda prevede di rinnovare un altro posto di direttore indipendente prima dell'Assemblea Annuale del 2025 attraverso un processo di ricerca guidato dal Comitato per la Nominazione e la Governance del Consiglio. Questi cambiamenti fanno parte degli sforzi di rinfrescamento del Consiglio di Evolent, con cinque nuovi direttori indipendenti aggiunti negli ultimi tre anni.
Le nomine sono in linea con l'impegno di Evolent per una forte governance aziendale e una collaborazione con gli azionisti. L'aggiunta di Springstubb rafforza l'esperienza del Consiglio nei mercati dei capitali e nella finanza, mentre Jelinek porta con sé l'esperienza di Managing Partner di Czech One Capital Partners e ex EVP di CVS Health.
Evolent Health (NYSE: EVH) anunció cambios significativos en su Junta Directiva. Rick Jelinek, quien se unió como director independiente en 2023, se convertirá en Presidente de la Junta en la Asamblea Anual de 2025, sucediendo a Cheryl Scott. Además, Brendan Springstubb ha sido nombrado nuevo director independiente, aportando más de 20 años de experiencia en inversiones en el sector salud.
La empresa planea renovar otro puesto de director independiente antes de la Asamblea Anual de 2025 a través de un proceso de búsqueda liderado por el Comité de Nominaciones y Gobernanza de la Junta. Estos cambios son parte de los esfuerzos continuos de Evolent para refrescar la Junta, con cinco nuevos directores independientes añadidos en los últimos tres años.
Las designaciones están alineadas con el compromiso de Evolent con una sólida gobernanza corporativa y colaboración con los accionistas. La adición de Springstubb refuerza la experiencia del consejo en mercados de capital y finanzas, mientras que Jelinek aporta su experiencia como Managing Partner de Czech One Capital Partners y ex EVP de CVS Health.
에볼런트 헬스 (NYSE: EVH)가 이사회에 중대한 변화를 발표했습니다. 2023년 독립 이사로 합류한 릭 젤리넥이 2025년 정기 주주총회에서 의장으로 취임하며 체릴 스콧의 뒤를 잇습니다. 또한, 브렌단 스프링스텁이 새로운 독립 이사로 임명되어 20년 이상의 의료 투자 경험을 제공합니다.
회사는 2025년 정기 주주총회 이전에 이사회 명단 갱신을 위해 독립 이사 자리를 또 하나 새로 지정할 계획이며, 이는 이사회 인사 및 거버넌스 위원회가 주도하는 검색 프로세스를 통해 이루어집니다. 이러한 변화는 에볼런트의 지속적인 이사회 갱신 노력의 일환으로, 지난 3년 동안 5명의 새로운 독립 이사가 추가되었습니다.
이번 임명은 에볼런트의 강력한 기업 거버넌스 및 주주 협력에 대한 의지를 반영합니다. 스프링스텁의 추가는 이사회의 자본 시장 및 재무 전문성을 강화하고, 젤리넥은 체코 원 캐피탈 파트너스의 관리 파트너이자 CVS 헬스의 전무이사로서의 경험을 제공합니다.
Evolent Health (NYSE: EVH) a annoncé des changements significatifs dans son Conseil d'Administration. Rick Jelinek, qui a rejoint en tant qu'administrateur indépendant en 2023, deviendra Président du Conseil lors de l'Assemblée Annuelle de 2025, succédant à Cheryl Scott. De plus, Brendan Springstubb a été nommé nouveau directeur indépendant, apportant plus de 20 ans d'expérience en investissement dans le secteur de la santé.
L'entreprise prévoit de renouveler un autre poste de directeur indépendant avant l'Assemblée Annuelle de 2025 grâce à un processus de recherche dirigé par le Comité de Nominations et de Gouvernance du Conseil. Ces changements font partie des efforts d'actualisation continue du conseil d'Evolent, avec cinq nouveaux administrateurs indépendants ajoutés au cours des trois dernières années.
Les nominations s'alignent avec l'engagement d'Evolent envers une gouvernance d'entreprise forte et la collaboration avec les actionnaires. L'ajout de Springstubb renforce l'expertise du conseil en matière de marchés de capitaux et de finances, tandis que Jelinek apporte son expérience en tant que Managing Partner de Czech One Capital Partners et ancien EVP de CVS Health.
Evolent Health (NYSE: EVH) hat bedeutende Veränderungen im Vorstand angekündigt. Rick Jelinek, der 2023 als unabhängiger Direktor beigetreten ist, wird beim jährlichen Treffen 2025 den Vorsitz übernehmen und Cheryl Scott nachfolgen. Darüber hinaus wurde Brendan Springstubb als neuer unabhängiger Direktor ernannt, der über 20 Jahre Erfahrung im Bereich Gesundheitsinvestitionen mitbringt.
Das Unternehmen plant, vor dem jährlichen Treffen 2025 einen weiteren unabhängigen Direktor durch einen von dem Nominierungs- und Governance-Ausschuss des Vorstands geleiteten Suchprozess zu ernennen. Diese Veränderungen sind Teil von Evolents kontinuierlichen Bemühungen um die Erneuerung des Vorstands, wobei in den letzten drei Jahren fünf neue unabhängige Direktoren hinzugefügt wurden.
Die Ernennungen stehen im Einklang mit Evolents Engagement für eine starke Unternehmensführung und die Zusammenarbeit mit den Aktionären. Die Hinzufügung von Springstubb stärkt die Expertise des Vorstands in den Bereichen Kapitalmärkte und Finanzen, während Jelinek Erfahrungen als Managing Partner von Czech One Capital Partners und ehemaliger EVP von CVS Health mitbringt.
- Addition of two experienced directors strengthening healthcare and finance expertise
- Demonstrated commitment to board refreshment with 5 new independent directors in 3 years
- Support from major shareholder Engaged Capital
- None.
Richard "Rick" Jelinek to Be Named Chair of the Board at 2025 Annual Meeting
Company Continues Board Refreshment Efforts with Brendan Springstubb's Appointment as New Independent Director
Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott. Mr. Jelinek is currently Managing Partner of Czech One Capital Partners and previously served as Executive Vice President of CVS Health.
In addition, Brendan Springstubb has joined the Evolent Board as an independent director. Mr. Springstubb brings more than 20 years of experience investing in premier healthcare companies and has extensive experience working with public companies on strategy, investor communications and value creation.
Further, the Board intends to refresh an independent director seat in advance of the 2025 Annual Meeting pursuant to a previously initiated search process being overseen by the Board's Nominating and Governance Committee. With the additions announced today, Evolent will have added five new independent directors to the Board in the past three years.
Ms. Scott said, "The rotation of the Chair role and our continued Board refreshment builds on actions previously taken by the Evolent Board to ensure that our corporate governance is aligned with best-in-class practices. It has been an honor to serve as Chair of the Board since 2022."
Ms. Scott continued, "As we pursue investments and initiatives that drive both better health outcomes and a strong future for the Company, we are pleased to deepen the capital markets and finance experience on Evolent's Board with Brendan's appointment."
Glenn W. Welling, Founder and CIO of Engaged Capital, one of Evolent's largest shareholders commented, "Having worked with Brendan for over 15 years, I know he will be a strong shareholder advocate in the Evolent boardroom. As evidenced by its consistent new business wins and high customer retention, Evolent is a critical service provider to its clients, and I am confident Brendan will be a great partner to Seth and the team as Evolent leverages its strong competitive position to create value for shareholders."
Seth Blackley, co-founder and Chief Executive Officer of Evolent stated, "Evolent has long benefitted from a Board that brings skills, experience and a shared commitment to advance our mission. Rick and Brendan will be critical to ensuring we are creating value for all our stakeholders going forward and I also want to thank Cheryl for leading the Board the last 3 years."
About Brendan Springstubb
Mr. Springstubb joins our Board with two decades of experience leading investments in publicly traded healthcare companies. He is currently Principal of Bedell Canyon LLC, where he provides analysis, engagement strategy, and fundraising assistance to public equity investment firms, with an emphasis on companies in the healthcare sector.
Prior to Bedell, Mr. Springstubb was a Principal at Engaged Capital, LLC, one of Evolent's largest shareholders for the past four years, where he was responsible for sourcing and managing investments primarily in the healthcare industry. Previously, he held multiple roles at Relational Investors, LLC, where he covered the healthcare sector.
Mr. Springstubb was previously a member of the SunOpta Inc. Board of Directors, serving as the Chair of the Compensation Committee.
Mr. Springstubb holds a master's degree from Johns Hopkins University in biotechnology and a bachelor's degree in molecular biology and economics from
About Evolent Health
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.
Forward-Looking Statements – Cautionary Language
Certain statements made in this release and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, future appointments to our board of directors, trends in our businesses, prospective services, future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA. These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Our Annual Report on Form 10-K for the year ended December 31, 2023, as amended, subsequent Quarterly Reports on Form 10-Q and other documents filed with the
Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this release.
Evolent Contact
Seth R. Frank
Vice President, Investor Relations
sfrank@evolent.com
571-895-3919
View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-health-announces-changes-to-board-of-directors-302366851.html
SOURCE Evolent Health, Inc.
FAQ
Who will become the new Board Chair of Evolent Health (EVH) in 2025?
How many new independent directors has EVH added to its board in the past three years?
Who is the newest independent director appointed to Evolent Health's board?
What changes is EVH planning for its board before the 2025 Annual Meeting?
